268 related articles for article (PubMed ID: 25541937)
41. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
42. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
43. Use of Ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials.
Hatano M; Wakuta M; Yamamoto K; Arai E; Enoki M; Fujimoto K; Yamauchi K; Ishikawa K; Sonoda KH; Kimura K
Sci Rep; 2023 Dec; 13(1):22965. PubMed ID: 38151499
[TBL] [Abstract][Full Text] [Related]
44. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.
Kang SW; Park SC; Cho HY; Kang JH
Am J Ophthalmol; 2007 Dec; 144(6):878-885. PubMed ID: 17936715
[TBL] [Abstract][Full Text] [Related]
45. [Intravitreal triamcinolone combined with grid laser photocoagulation for patients with cystoid macular edema and advanced diabetic retinopathy: pilot study].
Arévalo JF; Fernández CF; Mendoza AJ; García RA; Arévalo FA
Arch Soc Esp Oftalmol; 2013 Oct; 88(10):373-9. PubMed ID: 24060300
[TBL] [Abstract][Full Text] [Related]
46. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
47. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.
Pielen A; Mirshahi A; Feltgen N; Lorenz K; Korb C; Junker B; Schaefer C; Zwiener I; Hattenbach LO;
Acta Ophthalmol; 2015 Feb; 93(1):e29-37. PubMed ID: 25042729
[TBL] [Abstract][Full Text] [Related]
48. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials.
Yanagida Y; Ueta T
Retina; 2014 Apr; 34(4):629-35. PubMed ID: 24667549
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
50. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
[TBL] [Abstract][Full Text] [Related]
51. Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?
Turkoglu EB; Celık E; Aksoy N; Bursalı O; Ucak T; Alagoz G
J Diabetes Complications; 2015; 29(4):540-3. PubMed ID: 25817172
[TBL] [Abstract][Full Text] [Related]
52. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
53. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
[TBL] [Abstract][Full Text] [Related]
54. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
Naser H; Koss MJ; Singh P; Koch F
Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
56. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
Solaiman KA; Diab MM; Dabour SA
Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
[TBL] [Abstract][Full Text] [Related]
58. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
59. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials.
Si JK; Tang K; Bi HS; Guo DD; Guo JG; Du YX; Cui Y; Pan XM; Wen Y; Wang XR
Int J Ophthalmol; 2014; 7(3):541-9. PubMed ID: 24967206
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
Mitchell P; Annemans L; Gallagher M; Hasan R; Thomas S; Gairy K; Knudsen M; Onwordi H
Br J Ophthalmol; 2012 May; 96(5):688-93. PubMed ID: 22399690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
